Researchers have proposed that blocking facial feedback via glabellar-region botulinum toxin injections (GBTX) can reduce depression. Random-effects meta-analyses of studies that administered GBTX to individuals with depression indicate that, 6 weeks postintervention, GBTX groups were significantly less depressed compared to placebo groups (d = 0.83) and pretreatment levels (d = 1.57). However, we noted the following concerns: (a) effect sizes were extraordinarily large, (b) authors failed to provide information to compute 51% of relevant effect sizes, (c) 96% of effect sizes came from studies conducted by investigators with conflicts of interest, (d) there is some evidence of publication bias, and (e) studies used ineffective blinding procedures. These considerations suggest that confidence in GBTX as a treatment for depression is premature.
AdelmannP. K.ZajoncR. B. (1989). Facial efference and the experience of emotion. Annual Review of Psychology, 40(1), 249–280.
2.
AlamM.BarrettK. C.HodappR. M.ArndtK. A. (2008). Botulinum toxin and the facial feedback hypothesis: Can looking better make you feel happier?Journal of the American Academy of Dermatology, 58(6), 1061–1072.
AscherB.ZakineB.KestemontP.BaspeyrasM.BougaraA.SantiniJ. (2004). A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology, 51(2), 223–233.
9.
BagbyR. M.RyderA. G.SchullerD. R.MarshallM. B. (2004). The Hamilton Depression Rating Scale: Has the gold standard become a lead weight?American Journal of Psychiatry, 161(12), 2163–2177.
10.
BaileyJ.CoppenA. (1976). A comparison between the Hamilton Rating Scale and the Beck Inventory in the measurement of depression. British Journal of Psychiatry, 128(5), 486–489.
11.
BeckA. T. (1979). Cognitive therapy and the emotional disorders. New York, NY: Penguin.
12.
BeckA. T.BredemeierK. (2016). A unified model of depression: Integrating clinical, cognitive, biological, and evolutionary perspectives. Clinical Psychological Science, 4(4), 596–619.
13.
BeckA. T.SteerR. A.GarbinM. G. (1988). Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review, 8(1), 77–100.
14.
BeerK. (2010). Cost effectiveness of botulinum toxins for the treatment of depression: Preliminary observations. Journal of Drugs in Dermatology, 9(1), 27–30.
15.
BekelmanJ. E.LiY.GrossC. P. (2003). Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA, 289(4), 454–465.
16.
BemD. J. (1967). Self perception: An alternative interpretation of cognitive dissonance phenomena. Psychological Review, 74(3), 183–200.
17.
BerkowitzD. (2017). Botox nation: Changing the face of America. New York, NY: NYU Press.
18.
BlumenfeldA. M.TepperS. J.RobbinsL. D.Manack AdamsA.BuseD. C.OrejudosA.SilbersteinS. D. (2019). Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. Journal of Neurology, Neurosurgery & Psychiatry, 90. doi:10.1136/jnnp-2018-319290
19.
BorensteinM. (2009). Effect sizes for continuous data. In CooperH.HedgesL. V.ValentineJ. C. (Eds.), The handbook of research synthesis and meta-analysis (pp. 221–235). New York, NY: Russel Sage Foundation.
20.
BorensteinM.HedgesL. V.HigginsJ. P.RothsteinH. R. (2009). Introduction to meta-analysis. Chichester, UK: John Wiley & Sons.
21.
BoumparisN.KaryotakiE.KleiboerA.HofmannS. G.CuijpersP. (2016). The effect of psychotherapeutic interventions on positive and negative affect in depression: A systematic review and meta-analysis. Journal of Affective Disorders, 202, 153–162. doi:10.1016/j.jad.2016.05.019
BrinM. F. (1997). Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle & Nerve, 20(6), 146–168.
24.
BylsmaL. M.MorrisB. H.RottenbergJ. (2008). A meta-analysis of emotional reactivity in major depressive disorder. Clinical Psychology Review, 28(4), 676–691.
ChughS.ChhabriaA.JungS.KrugerT. H. C.WollmerM. A. (2018). Botulinum toxin as a treatment for depression in a real-world setting. Journal of Psychiatric Practice, 24(1), 15–20.
28.
CoanJ. A.AllenJ. B.Harmon-JonesE. (2001). Voluntary facial expression and hemispheric asymmetry over the frontal cortex. Psychophysiology, 38(6), 912–925.
29.
CohenJ. (1988). Statistical power analysis for the behavioral sciences (Vol. 2). New York, NY: Lawrence Erlbaum Associates.
30.
ColesN. A.LarsenJ. T.LenchH. C. (2019). A meta-analysis of the facial feedback literature: Effects of facial feedback on emotional experience are small and variable. Psychological Bulletin, 145(6), 610–651.
31.
ColesN. A.MarchD. S.Marmolejo-RamosF.BanarueeH.ButcherN.CavalletM.. . .GorbunovaE. (2019). The Many Smiles Collaboration: A multi-lab foundational test of the facial feedback hypothesis. Retrieved from https://doi.org/10.31234/osf.io/cvpuw
32.
DarwinC. (1872). The expression of the emotions in man and animals. London, UK: William Clowes and Sons.
33.
DavisJ. I. (2008). The connection between facial expression and emotional experience (Doctoral dissertation). Retrieved from ProQuest Dissertations & Theses Global. (Accession No. 3305213).
34.
DavisJ. I.SenghasA.BrandtF.OchsnerK. N. (2010). The effects of BOTOX injections on emotional experience. Emotion, 10(3), 433–440.
35.
De BoulleK.FagienS.SommerB.GlogauR. (2010). Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction. Clinical Interventions in Aging, 5, 101–118.
36.
DuclosS. E.LairdJ. D. (2001). The deliberate control of emotional experience through control of expressions. Cognition and Emotion, 15(1), 27–56.
37.
DuvalS.TweedieR. (2000). Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56(2), 455–463.
38.
EkmanP. (1979). Biological and cultural contributions to body and facial movement. In BlackingJ. (Ed.), Anthropology of the body (pp. 34–38). London, UK: Routledge.
39.
EkmanP.DavidsonR. J.FriesenW. V. (1990). The Duchenne smile: Emotional expression and brain physiology. II. Journal of Personality and Social Psychology, 58(2), 342–353.
40.
FagienS.StoneC.CoxS. E.WerschlerW. P. (2007). Patient-reported outcomes in subjects receiving botulinum toxin type A (BoNTA) treatment for moderate to severe glabellar rhytids: Results from two randomized, double-blind, placebo-controlled studies. Journal of the American Academy of Dermatology, 56(2). doi:10.1016/j.jaad.2006.10.897
41.
FinziE. (2013). The face of emotion: How Botox affects our moods and relationships. London, UK: St. Martin’s Press.
42.
FinziE. (2018). Botulinum toxin for depression more than skin deep. Dermatologic Surgery, 44(10), 1363–1365.
43.
FinziE.RosenthalN. E. (2014). Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial. Journal of Psychiatric Research, 52, 1–6. doi:10.1016/j.jpsychires.2013.11.006
44.
FinziE.RosenthalN. E. (2016). Emotional proprioception: Treatment of depression with afferent facial feedback. Journal of Psychiatric Research, 80, 93–96.
45.
FinziE.WassermanE. (2006). Treatment of depression with botulinum toxin A: A case series. Dermatologic Surgery, 32(5), 645–649.
46.
FörsterJ.StrackF. (1996). Influence of overt head movements on memory for valenced words: A case of conceptual-motor compatibility. Journal of Personality and Social Psychology, 71(3), 421–430.
47.
FrancoA.MalhotraN.SimonovitsG. (2014). Publication bias in the social sciences: Unlocking the file drawer. Science, 345(6203), 1502–1505.
48.
FriedmanL. S.RichterE. D. (2004). Relationship between conflicts of interest and research results. Journal of General Internal Medicine, 19(1), 51–56.
FromageG. (2018). Exploring the effects of botulinum toxin type A injections on depression. Aesthetic Nursing, 7(6), 315–317.
51.
GellhornE. (1958a). The influence of curare on hypothalamic excitability and the electroencephalogram. Electroencephalography and Clinical Neurophysiology, 10(4), 697–703.
52.
GellhornE. (1958b). The physiological basis of neuromuscular relaxation. AMA Archives of Internal Medicine, 102(3), 392–399.
53.
GellhornE. (1964). Motion and emotion: The role of proprioception in the physiology and pathology of the emotions. Psychological Review, 71(6), 457–472.
54.
GelmanA.CarlinJ. (2014). Beyond power calculations: Assessing Type S (sign) and Type M (magnitude) errors. Perspectives on Psychological Science, 9(6), 641–651.
55.
GendronM.BarrettL. F. (2009). Reconstructing the past: A century of ideas about emotion in psychology. Emotion Review, 1, 316–339.
56.
GeschwindN.NicolsonN. A.PeetersF.van OsJ.Barge-SchaapveldD.WichersM. (2011). Early improvement in positive rather than negative emotion predicts remission from depression after pharmacotherapy. European Neuropsychopharmacology, 21(3), 241–247.
57.
GurevitchJ.KorichevaJ.NakagawaS.StewartG. (2018). Meta-analysis and the science of research synthesis. Nature, 555, 175–182.
58.
HanC.ParkG.-Y.WangS.-M.LeeS.-Y.LeeS.-J.BahkW.-M.PaeC.-U. (2012). Can botulinum toxin improve mood in depressed patients?Expert Review of Neurotherapeutics, 12(9), 1049–1051.
HedgesL. V.PigottT. D. (2001). The power of statistical tests in meta-analysis. Psychological Methods, 6(3), 203–217.
61.
HedgesL. V.TiptonE.JohnsonM. C. (2010). Robust variance estimation in meta-regression with dependent effect size estimates. Research Synthesis Methods, 1(1), 39–65.
62.
HedgesL. V.VeveaJ. L. (1998). Fixed- and random-effects models in meta-analysis. Psychological Methods, 3(4), 486–504.
63.
HexselD.BrumC.SiegaC.Schilling-SouzaJ.Dal’FornoT.HeckmannM.RodriguesT. C. (2013). Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines. Dermatologic Surgery, 39(7), 1088–1096.
IzardC. E. (1977). Human emotions. New York, NY: Plenum.
66.
IzardC. E. (1993). Four systems for emotion activation: Cognitive and noncognitive processes. Psychological Review, 100(1), 68–90.
67.
IzardC. E. (2007). Basic emotions, natural kinds, emotion schemas, and a new paradigm. Perspectives on Psychological Science, 2(3), 260–280.
68.
JagsiR.SheetsN.JankovicA.MotomuraA. R.AmarnathS.UbelP. A. (2009). Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer, 115(12), 2783–2791.
69.
JamesW. (1884). What is an emotion?Mind, 9(34), 188–205.
70.
JamesW. (1894). Discussion: The physical basis of emotion. Psychological Review, 1(5), 516–529.
71.
KliemS.MößleT.ZengerM.BrählerE. (2014). Reliability and validity of the Beck Depression Inventory-Fast Screen for medical patients in the general German population. Journal of Affective Disorders, 156, 236–239.
72.
KrügerT. H. C.JungS.WollmerM. A. (2016). Botulinumtoxin – Ein neuer wirkstoff in der psychopharmakotherapie? [Botulinum toxin – A new drug in psychopharmacotherapy?]. Psychopharmakotherapie, 23(1), 2–7.
73.
KungS.AlarconR. D.WilliamsM. D.PoppeK. A.Jo MooreM.FryeM. A. (2013). Comparing the Beck Depression Inventory-II (BDI-II) and Patient Health Questionnaire (PHQ-9) depression measures in an integrated mood disorders practice. Journal of Affective Disorders, 145(3), 341–343.
74.
LairdJ. D. (1974). Self-attribution of emotion: The effects of expressive behavior on the quality of emotional experience. Journal of Personality and Social Psychology, 29(4), 475–486.
75.
LairdJ. D.BreslerC. (1992). The process of emotional experience: A self-perception theory. In ClarkM. S. (Ed.), Emotion (pp. 213–234). Thousand Oaks, CA: SAGE.
76.
LairdJ. D.StroutS. (2007). Emotional behaviors as emotional stimuli. In CoanJ. A.AllenJ. J. B. (Eds.), Handbook of emotion elicitation and assessment (pp. 54–64). New York, NY: Oxford University Press.
77.
LakensD. (2013). Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Frontiers in Psychology, 4, 1–11. doi:10.3389/fpsyg.2013.00863
78.
LevensonR. W.CarstensenL. L.FriesenW. V.EkmanP. (1991). Emotion, physiology, and expression in old age. Psychology and Aging, 6(1), 28–35.
79.
LevensonR. W.EkmanP.FriesenW. V. (1990). Voluntary facial action generates emotion-specific autonomic nervous system activity. Psychophysiology, 27(4), 363–384.
80.
LevensonR. W.EkmanP.HeiderK.FriesenW. V. (1992). Emotion and autonomic nervous system activity in the Minangkabau of West Sumatra. Journal of Personality and Social Psychology, 62(6), 972–988.
81.
LewisM. B. (2018). The interactions between botulinum-toxin-based facial treatments and embodied emotions. Scientific Reports, 8(1), 1–10. Retrieved from https://www.nature.com/articles/s41598-018-33119-1
82.
LewisM. B.BowlerP. J. (2009). Botulinum toxin cosmetic therapy correlates with a more positive mood. Journal of Cosmetic Dermatology, 8(1), 24–26.
83.
LexchinJ.BeroL. A.DjulbegovicB.ClarkO. (2003). Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ, 326(7400), 1167–1170.
84.
LyubomirskyS. (2008). The how of happiness: A scientific approach to getting the life you want. New York, NY: Penguin.
85.
MacaskillP.WalterS. D.IrwigL. (2001). A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine, 20(4), 641–654.
86.
MacCallumR. C.ZhangS.PreacherK. J.RuckerD. D. (2002). On the practice of dichotomization of quantitative variables. Psychological Methods, 7(1), 19–40.
87.
MagidM.FinziE.KrugerT. H. C.RobertsonH. T.KeelingB. H.JungS.. . .WollmerM. A. (2015). Treating depression with botulinum toxin: A pooled analysis of randomized controlled trials. Pharmacopsychiatry, 48(6), 205–210.
88.
MagidM.KeelingB. H.ReichenbergJ. S. (2015). Neurotoxins: Expanding uses of neuromodulators in medicine—Major depressive disorder. Plastic and Reconstructive Surgery, 136(5), 111–119.
89.
MagidM.ReichenbergJ. S. (2015). Botulinum toxin for depression? An idea that’s raising some eyebrows. Current Psychiatry, 14(11), 43–56.
90.
MagidM.ReichenbergJ. S.PothP. E.RobertsonH. T.LaVioletteA. K.KrugerT. H. C.WollmerM. A. (2014). Treatment of major depressive disorder using botulinum toxin A: A 24-week randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry, 75(8), 837–844.
91.
MandrioliD.KearnsC. E.BeroL. A. (2016). Relationship between research outcomes and risk of bias, study sponsorship, and author financial conflicts of interest in reviews of the effects of artificially sweetened beverages on weight outcomes: A systematic review of reviews. PLoS ONE, 11(9), 1–20. doi:10.1371/journal.pone.0162198
92.
McIntoshD. N.ZajoncR. B.VigP. S.EmerickS. W. (1997). Facial movement, breathing, temperature, and affect: Implications of the vascular theory of emotional efference. Cognition and Emotion, 11(2), 171–196.
MorrisB. H.BylsmaL. M.RottenbergJ. (2009). Does emotion predict the course of major depressive disorder? A review of prospective studies. British Journal of Clinical Psychology, 48(3), 255–273.
ParsaikA. K.MascharenhasS. S.HashmiA.ProkopL. J.JohnV.OkusagaO.SinghB. (2016). Role of botulinum toxin in depression. Journal of Psychiatric Practice, 22(2), 99–110.
99.
PriceT. F.Harmon-JonesE. (2015). Embodied emotion: The influence of manipulated facial and bodily states on emotive responses. Wiley Interdisciplinary Reviews: Cognitive Science, 6, 461–473.
100.
ReichenbergJ. S.HauptmanA. J.RobertsonH. T.FinziE.KrugerT. H. C.WollmerM. A.MagidM. (2016). Botulinum toxin for depression: Does patient appearance matter?Journal of the American Academy of Dermatology, 74(1), 171–173.
101.
ReynoldsW. M.KobakK. A. (1995). Reliability and validity of the Hamilton Depression Inventory: A paper-and-pencil version of the Hamilton Depression Rating Scale Clinical Interview. Psychological Assessment, 7(4), 472–483.
102.
RothsteinH. R.SuttonA. J.BorensteinM. (2006). Publication bias in meta-analysis: Prevention, assessment and adjustments. Chichester, UK: John Wiley & Sons.
103.
RottenbergJ. (2017). Emotions in depression: What do we really know?Annual Review of Clinical Psychology, 13, 241–265.
104.
RoyA.CampbellM. K. (2013). A unifying framework for depression: Bridging the major biological and psychosocial theories through stress. Clinical and Investigative Medicine, 36(4), E170–E190.
105.
RudorferM. V. (2018). Botulinum toxin: Does it have a place in the management of depression?CNS Drugs, 32(2), 97–100.
106.
SchererK. R. (2009). The dynamic architecture of emotion: Evidence for the component process model. Cognition and Emotion, 23(7), 1307–1351.
107.
SchnallS.LairdJ. D. (2003). Keep smiling: Enduring effects of facial expressions and postures on emotional experience and memory. Cognition and Emotion, 17(5), 787–797.
108.
SeligmanM. E. P. (1972). Learned helplessness. Annual Review of Medicine, 23(1), 407–412.
SmithC. A.KirbyL. D. (2004). Appraisal as a pervasive determinant of anger. Emotion, 4(2), 133–138.
112.
SoussignanR. (2002). Duchenne smile, emotional experience, and autonomic reactivity: A test of the facial feedback hypothesis. Emotion, 2(1), 52–74.
113.
SoussignanR. (2004). Regulatory function of facial actions in emotion processes. In ColumbusF. (Ed.), Advances in psychology research (Vol. 31, pp. 171–196). Hauppauge, NY: Nova Science.
114.
StanleyT. D. (2017). Limitations of PET-PEESE and other meta-analysis methods. Social Psychological and Personality Science, 8(5), 581–591.
115.
StanleyT. D.DoucouliagosH. (2014). Meta-regression approximations to reduce publication selection bias. Research Synthesis Methods, 5(1), 60–78.
116.
SterneJ. A. C.SuttonA. J.IoannidisJ. P. A.TerrinN.JonesD. R.LauJ.. . .HigginsJ. P. T. (2011). Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ, 343(7818), 1–8. doi:10.1136/bmj.d4002
117.
StotlandM. A.KowalskiJ. W.RayB. B. (2007). Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: Results from a prospective open-label study. Plastic and Reconstructive Surgery, 120(5), 1386–1393.
118.
StrackF.MartinL. L.StepperS. (1988). Inhibiting and facilitating conditions of the human smile: A nonobtrusive test of the facial feedback hypothesis. Journal of Personality and Social Psychology, 54(5), 768–777.
119.
TomkinsS. S. (1962). Affect imagery consciousness: The positive affects. New York, NY: Springer.
120.
TremaineA. M.McCulloughJ. L. (2010). Botulinum toxin type A for the management of glabellar rhytids. Clinical, Cosmetic and Investigational Dermatology, 3, 15–23.
121.
TurnerE. H.MatthewsA. M.LinardatorsE.TellR. A.RosenthalR. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. The New England Journal of Medicine, 358(3), 252–260.
122.
ValentineJ. C.PigottT. D.RothsteinH. R. (2010). How many studies do you need?: A primer on statistical power for meta-analysis. Journal of Educational and Behavioral Statistics, 35(2), 215–247.
123.
Van den NoortgateW.Lopez-LopezJ. A.Marin-MartinezF.Sanchez-MecaJ. (2015). Meta-analysis of multiple outcomes: A multilevel approach. Behavior Research Methods, 47(4), 1274–1294.
124.
VeveaJ. L.HedgesL. V. (1995). A general linear model for estimating effect size in the presence of publication bias. Psychometrika, 60(3), 419–435.
125.
VeveaJ. L.WoodsC. M. (2005). Publication bias in research synthesis: Sensitivity analysis using a priori weight functions. Psychological Methods, 10(4), 428–443.
WangY.-P.GorensteinC. (2013). Psychometric properties of the Beck Depression Inventory-II: A comprehensive review. Brazilian Journal of Psychiatry, 35(4), 416–431.
128.
WollmerM. A.De BoerC.KalakN.BeckJ.GötzT.SchmidtT.. . .KrugerT. H. C. (2012). Facing depression with botulinum toxin: A randomized controlled trial. Journal of Psychiatric Research, 46(5), 574–581.
129.
WollmerM. A.KalakN.JungS.de BoerC.MagidM.ReichenbergJ. S.. . .KrugerT. H. C. (2014). Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial. Frontiers in Psychiatry, 5. doi:10.3389/fpsyt.2014.00036
130.
WollmerM. A.MagidM.KrugerT. H. C. (2014). Botulinum toxin treatment in depression. In BewleyA.TaylorR. E.ReichenbergJ. S.MagidM. (Eds.), Practical psychodermatology (pp. 216–219). Chichester, UK: John Wiley & Sons.
131.
YoungS. N. (2013). Single treatments that have lasting effects: Some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. Journal of Psychiatry and Neuroscience, 38(2), 78–83.
132.
ZajoncR. B. (1985). Emotion and facial efference: A theory reclaimed. Science, 228(4695), 15–21.
133.
ZajoncR. B.MurphyS. T.InglehartM. (1989). Feeling and facial efference: Implications of the vascular theory of emotion. Psychological Review, 96(3), 395–416.
134.
ZajoncR. B.MurphyS. T.McIntoshD. N. (1993). Brain temperature and subjective emotional experience. In LewisM.HavilandJ. M. (Eds.), Handbook of emotions (pp. 209–220). New York, NY: Guilford Press.
135.
ZamanianA.JolfaeiA. G.MehranG.AzizianZ. (2017). Efficacy of Botox versus placebo for treatment of patients with major depression. Iran Journal of Public Health, 46(7), 982–984.
136.
ZannaM. P.CooperJ. (1974). Dissonance and the pill: An attribution approach to studying the arousal properties of dissonance. Journal of Personality and Social Psychology, 29(5), 703–709.
